Calliditas Therapeutics AB (publ) (NASDAQ:CALT) was the target of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 41,400 shares, a decrease of 56.0% from the September 15th total of 94,000 shares. Based on an average daily trading volume, of 31,400 shares, the days-to-cover ratio is presently 1.3 days.
Shares of CALT stock opened at $21.95 on Thursday. The stock’s fifty day moving average price is $25.13 and its two-hundred day moving average price is $27.62. The company has a market cap of $574.45 million, a PE ratio of -7.92 and a beta of 2.78. Calliditas Therapeutics AB has a fifty-two week low of $20.15 and a fifty-two week high of $38.00.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its earnings results on Thursday, August 19th. The company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.04). Analysts expect that Calliditas Therapeutics AB will post -2.78 EPS for the current fiscal year.
A number of equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Calliditas Therapeutics AB (publ) from a “buy” rating to a “hold” rating in a research report on Friday, August 13th. SEB Equity Research assumed coverage on Calliditas Therapeutics AB (publ) in a research report on Wednesday, July 7th. They set a “buy” rating on the stock. Finally, SEB Equities started coverage on Calliditas Therapeutics AB (publ) in a research report on Wednesday, July 7th. They set a “buy” rating on the stock.
About Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy.
Featured Article: How to calculate the intrinsic value of a stock
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.